These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 30097614)

  • 21. Tumour-Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis.
    Lopes-Bastos BM; Jiang WG; Cai J
    Anticancer Res; 2016 Mar; 36(3):1119-26. PubMed ID: 26977007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mechanical microenvironment in cancer: How physics affects tumours.
    Nagelkerke A; Bussink J; Rowan AE; Span PN
    Semin Cancer Biol; 2015 Dec; 35():62-70. PubMed ID: 26343578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cross-Talk Between the Tumor Microenvironment, Extracellular Matrix, and Cell Metabolism in Cancer.
    Nazemi M; Rainero E
    Front Oncol; 2020; 10():239. PubMed ID: 32175281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Growth factors stimulate anabolic metabolism by directing nutrient uptake.
    Thompson CB; Bielska AA
    J Biol Chem; 2019 Nov; 294(47):17883-17888. PubMed ID: 31628187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Emerging Hallmarks of Cancer Metabolism.
    Pavlova NN; Thompson CB
    Cell Metab; 2016 Jan; 23(1):27-47. PubMed ID: 26771115
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting cancer with phosphodiesterase inhibitors.
    Savai R; Pullamsetti SS; Banat GA; Weissmann N; Ghofrani HA; Grimminger F; Schermuly RT
    Expert Opin Investig Drugs; 2010 Jan; 19(1):117-31. PubMed ID: 20001559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer.
    Marshall S
    Sci STKE; 2006 Aug; 2006(346):re7. PubMed ID: 16885148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic exchanges within tumor microenvironment.
    Chiarugi P; Cirri P
    Cancer Lett; 2016 Sep; 380(1):272-80. PubMed ID: 26546872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attacking the supply wagons to starve cancer cells to death.
    Selwan EM; Finicle BT; Kim SM; Edinger AL
    FEBS Lett; 2016 Apr; 590(7):885-907. PubMed ID: 26938658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular mechanisms for tumour resistance to chemotherapy.
    Pan ST; Li ZL; He ZX; Qiu JX; Zhou SF
    Clin Exp Pharmacol Physiol; 2016 Aug; 43(8):723-37. PubMed ID: 27097837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
    Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
    Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The tumour microenvironment: a novel target for cancer therapy.
    Hanna E; Quick J; Libutti SK
    Oral Dis; 2009 Jan; 15(1):8-17. PubMed ID: 18992016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.
    Lien EC; Lyssiotis CA; Cantley LC
    Recent Results Cancer Res; 2016; 207():39-72. PubMed ID: 27557534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. mTOR Inhibition Restores Amino Acid Balance in Cells Dependent on Catabolism of Extracellular Protein.
    Nofal M; Zhang K; Han S; Rabinowitz JD
    Mol Cell; 2017 Sep; 67(6):936-946.e5. PubMed ID: 28918901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies.
    Mimeault M; Hauke R; Batra SK
    Clin Pharmacol Ther; 2008 May; 83(5):673-91. PubMed ID: 17786164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.